Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Reexamination Certificate
2008-01-15
2008-01-15
Salimi, Ali R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
C424S204100, C424S229100
Reexamination Certificate
active
10343719
ABSTRACT:
Superior molecular vaccines comprise nucleic acids, including naked DNA and replicon RNA, that encode a fusion polypeptide that includes an antigenic peptide or polypeptide against which an immune response is desired. Fused to the antigenic peptide is an intercellular spreading protein, in particular a herpes virus protein VP22 or a homologue or functional derivative thereof. Preferred spreading proteins are VP22 from HSV-1 and Marek's disease virus. The nucleic acid can encode any antigenic epitope of interest, preferably an epitope that is processed and presented by MHC class I proteins. Antigens of pathogenic organisms and cells such as tumor cells are preferred. Vaccines comprising HPV-16 E7 oncoprotein are exemplified. Also disclosed are methods of using the vaccines to induce heightened T cell mediated immunity, in particular by cytotoxic T lymphocytes, leading to protection from or treatment of a tumor.
REFERENCES:
patent: 6017735 (2000-01-01), O'Hare et al.
patent: WO 98 32866 (1998-07-01), None
Michel Nico et al. “Improved Immunogenicity of Human Papillomavirus Type 16 E7 DNA After Fusion to the Herpes Simplex Virus 1 VP22 Gene” Barcelona, Spain, Jul. 23-28, 2000, Abstract 458, XP002201712.
Michel Nico et al. “Enhanced Immunogenicity of HPV 16 E7 Fusion Proteins in DNA Vaccination” Virology vol. 294, pp. 47-59, 2002, XP002201708.
Wolfgang W. Leitner, et al. “DNA and RNA-Based Vaccines: Principles, Progress and Prospects” Vaccine, vol. 18, pp. 765-777, Dec. 10, 1999, XP002201709.
G.J.P. Fernando et al. “Expression, Purification and Immunological Characterization of the Transforming Protein E7, From Cervical Cancer-Associated Human Papillomavirus Type 16” Clin. Exp. Immunol, vol. 115, pp. 397-403, 1999, XP002201710.
Wen-Fang Cheng et al. “Enhancement of Sindbis Virus Self-Replicating RNA Vaccine Potency by Linkage of Herpes Simplex Virus Type 1 VP22 Protein to Antigen” Journal of Virology, vol. 75, No. 5, pp. 2368-2376, Mar. 2001-03, XP002201711.
Gillian Elliott, et al., “Intercellular Trafficking and Protein Delivery by a Herpesvirus Structural Protein”, http://www.cell.com/cgi/content/full88/2/223/, Cell, vol. 88, 223-233, Jan. 1997, 12 pages.
Hung Chien-Fu
Wu Tzvv-Choou
Foley & Hoag LLP
Salimi Ali R.
The Johns Hopkins University
LandOfFree
Molecular vaccine linking intercellular spreading protein to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Molecular vaccine linking intercellular spreading protein to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Molecular vaccine linking intercellular spreading protein to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3937633